Final results from the Phase I study expansion cohort of the selective FGFR inhibitor Debio 1347 in patients with solid tumors harboring an FGFR gene fusion

Presented at ASCO 2020

James M. Cleary¹, Gopa Iyer², Do-Youn Oh³, Ingo K. Mellinghoff², Lipika Goyal⁴, Matthew CH Ng⁵, Funda Meric-Bernstam⁶, Ignacio Matos⁷, Tsu-Yi Chao⁸, Rafik Ait Sarkouh⁹, Kira Cretegny⁹, Yassin Marzaoui⁹, Valerie Nicolas-Metral⁹, Anna Pokorska-Bocci⁹, Marie-Claude Roubaudi-Fraschini⁹, Anne Vaslin⁹, Claudio Zanna9, Angela Zubel⁹, Josep Tabernero⁷, Keith Flaherty⁴, David Hyman²

 

1. Dana-Farber Cancer Institute, Boston, MA;
2. Memorial Sloan-Kettering Cancer Center,
3. Seoul National University Hospital, Seoul, Korea; New York, NY;
4. Massachusetts General Hospital Cancer Center, Boston, MA;
5. National Cancer Centre Singapore, Singapore;
6. The University of Texas MD Anderson Cancer Center, Houston, TX;
7. Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;
8. Taipei Medical Hospital University, Taipei, Taiwan;
9. Debiopharm International SA, Lausanne, Switzerland